Elevated mitochondrial metabolism in Down syndrome iPSCs reduces commitment to neuroectoderm
Related Experiment Video
Updated: Nov 1, 2026

In Vitro Modeling of Down Syndrome Neurogenesis Using Human-Induced Pluripotent Stem Cells
Published on: March 7, 2025
Malay Chaklader1, Guilherme Henrique Souza Bomfim2, Jiankun Zhu1
1Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA.
Abstract:
A key feature of Down syndrome (DS) is reduced neurogenesis. Here, we provide evidence that increased mitochondrial metabolism in DS stem cells reduces their ability to commit to neuroectoderm (NE), one of the earliest steps in the development of the nervous system. We show that mitochondria in induced pluripotent stem cells derived from individuals with DS (3S-iPSCs) have a higher membrane potential and increased capacity for calcium uptake via the mitochondrial calcium uniporter (MCU) compared to isogenic, euploid controls. Consequently, 3S-iPSCs proliferate faster and spend less time in G1 of the cell cycle. This reduces the opportunity for growth of a primary cilium, an important developmental signaling hub. Inhibiting MCU or slowing proliferation of 3S-iPSCs is sufficient to increase ciliation and improve commitment to NE. In summary, we provide evidence that a mitochondria-to-cilia signaling axis important during the earliest steps of neurogenesis is dysregulated in DS iPSCs.

